Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio ...

Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The increased price target reflects a more optimistic outlook for NX-5948's adoption in double-refractory CLL, drawing comparisons to post-label expansion sales of pirtobrutinib by LLY/Loxo. Investors ...

The increased price target reflects a more optimistic outlook for NX-5948's adoption in double-refractory CLL, drawing comparisons to post-label expansion sales of pirtobrutinib by LLY/Loxo.

The increased price target reflects a more optimistic outlook for NX-5948's adoption in double-refractory CLL, drawing comparisons to post-label expansion sales of pirtobrutinib by LLY/Loxo.

Eli Lilly has announced that the company will present data from studies of Jaypirca (pirtobrutinib) at the 66th American ...